Navigation Links
Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Date:4/10/2013

Alachua, FL (PRWEB) April 10, 2013

Nanotherapeutics, Inc., announced it has been awarded a Department of Defense’s (DOD) contract to establish Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) capability dedicated to meet the needs of the DOD. The MCM ADM capabilities established by Nanotherapeutics will allow the DOD to more efficiently and expeditiously develop Medical Countermeasures (MCM) to protect and treat military populations against chemical, biological, radiological, and nuclear (CBRN) attacks and outbreaks of naturally occurring emerging and genetically engineered infectious diseases.

The contract was granted to Nanotherapeutics, as the prime contractor, and its industry partners after a highly competitive bid process. The ultimate goal for the award is to reduce the overall time and cost associated with the development and manufacturing of Food and Drug Administration approved MCMs.

Headquartered in Alachua, FL, Nanotherapeutics will integrate into a new state-of-the-art facility flexible, single use, disposable equipment that can provide our military’s national security requirements for MCMs now and in the foreseeable future.

Nanotherapeutics has assembled a world class team of partners from throughout the United States to apply new biomanufacturing technologies with existing manufacturing capabilities for small molecule and biologic products that will provide the DOD with the ability to rapidly respond to CBRN events.

About Nanotherapeutics
Nanotherapeutics, Inc. is a privately held biopharmaceutical company with a major focus on developing a diversified proprietary pipeline of products having both biodefense and medical applications. Products under development include biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infectives, vaccines and orthopedics. The Company has one FDA cleared injectable biologic, NanoFUSE® DBM used by orthopedic surgeons as bone graft filler. Nanotherapeutics has in-house cGMP manufacturing, formulation, and expertise in pre-clinical and clinical product development as well as clinical trial management to support its products. Established in 1999, the Company employs several proprietary platform technologies to manipulate and enhance the properties of drug candidates. For more information, visit the Company website at http://www.nanotherapeutics.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10611645.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selenium, Ltd. Awarded $500,000 SBIR Grant for Biofouling Prevention Technology
2. BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
3. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
4. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
5. S&D Marketing Advertising Awarded WBENC Certification
6. Island Abbey Foods Ltd CEO John Rowe Has Been Awarded the 2013 Food Industry Leadership Award by Food in Canada Magazine
7. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
8. Fidelis Companies Certifies 14 Recruiters; Certified Personnel Consultant (CPC) and Certified Temporary-Staffing Specialist (CTS) Designation from NAPS Awarded
9. Boyd Coatings Awarded Workforce Training Grant
10. PNNL awarded $2.8 million to keep troops cool while using less fuel
11. University of Minnesota awarded $28 million grant to lead microelectronics development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):